[go: up one dir, main page]

MX2017013792A - INHIBIDORES DE íŸ-LACTAMASA Y USOS DE LOS MISMOS. - Google Patents

INHIBIDORES DE íŸ-LACTAMASA Y USOS DE LOS MISMOS.

Info

Publication number
MX2017013792A
MX2017013792A MX2017013792A MX2017013792A MX2017013792A MX 2017013792 A MX2017013792 A MX 2017013792A MX 2017013792 A MX2017013792 A MX 2017013792A MX 2017013792 A MX2017013792 A MX 2017013792A MX 2017013792 A MX2017013792 A MX 2017013792A
Authority
MX
Mexico
Prior art keywords
compounds
lactamase
application
drug resistance
lactamase inhibitor
Prior art date
Application number
MX2017013792A
Other languages
English (en)
Inventor
Wu Frank
Original Assignee
Xuanzhu Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xuanzhu Pharma Co Ltd filed Critical Xuanzhu Pharma Co Ltd
Publication of MX2017013792A publication Critical patent/MX2017013792A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a un compuesto de la Fórmula (l)-(IV) útil como inhibidor de íŸ-lactamasa, una sal farmacéuticamente aceptable, óster, solvato o estereoisómero del mismo, en donde R1, R2, M y el anillo A tienen definiciones como aquellas en la especificación. La presente invención se refiere además a métodos para preparar estos compuestos, composiciones farmacóuticas que comprenden estos compuestos, y usos de estos compuestos. Por ejemplo, los compuestos de la presente invención se pueden utilizar como inhibidores de íŸ-lactamasa, para el tratamiento y/o profilaxis de enfermedades provocadas por infecciones bacterianas, solución de problemas de resistencia a fármacos provocadas por íŸ-lactamasas, especialmente enfermedades resistentes a fármacos bacterianos provocados por metalo-íŸ-lactamasas tipo B. (ver Fórmulas).
MX2017013792A 2015-09-16 2016-08-18 INHIBIDORES DE íŸ-LACTAMASA Y USOS DE LOS MISMOS. MX2017013792A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510589021 2015-09-16
PCT/CN2016/095837 WO2017045510A1 (zh) 2015-09-16 2016-08-18 β-内酰胺酶抑制剂及其用途

Publications (1)

Publication Number Publication Date
MX2017013792A true MX2017013792A (es) 2018-07-06

Family

ID=58288544

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017013792A MX2017013792A (es) 2015-09-16 2016-08-18 INHIBIDORES DE íŸ-LACTAMASA Y USOS DE LOS MISMOS.

Country Status (10)

Country Link
US (1) US10167283B2 (es)
EP (1) EP3281942A4 (es)
JP (1) JP2018515481A (es)
KR (1) KR20170131661A (es)
CN (1) CN107531709B (es)
AU (1) AU2016322283A1 (es)
CA (1) CA2984024A1 (es)
MX (1) MX2017013792A (es)
TW (1) TWI610930B (es)
WO (1) WO2017045510A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108778270B (zh) * 2016-03-31 2021-07-30 吉林四环制药有限公司 一种抗菌组合物及其用途
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
WO2018234962A1 (en) * 2017-06-20 2018-12-27 Wockhardt Limited Process for o-sulfonation of 1,6-diazabicyclo[3.2.1]octane compounds
CN109400521B (zh) * 2017-08-18 2020-05-08 新发药业有限公司 一种改进的5r-苄氧氨基哌啶-2s-甲酸酯、其草酸盐的制备方法
CN109568323B (zh) * 2017-09-29 2022-09-30 吉林四环制药有限公司 抗菌组合物及其用途
EP3676247B8 (en) 2017-10-02 2023-04-12 Arixa Pharmaceuticals, Inc. Aztreonam derivatives and uses thereof
US11897844B2 (en) 2018-09-21 2024-02-13 Api Corporation Method for producing amino acid derivatives
CA3114618C (en) 2018-10-01 2023-09-05 Arixa Pharmaceuticals, Inc. Derivatives of relebactam and uses thereof
SG11202108905UA (en) 2019-03-12 2021-09-29 Arixa Pharmaceuticals Inc Crystalline form of an avibactam derivative
US11565999B2 (en) 2019-04-25 2023-01-31 Arixa Pharmaceuticals, Inc. Methods of synthesizing aztreonam derivatives
CN110840897B (zh) * 2019-11-28 2023-08-08 河北旺发生物科技有限公司 金属β-内酰胺酶抑制剂
WO2022047603A1 (en) * 2020-09-01 2022-03-10 Ningxia Academy Of Agriculture And Forestry Sciences Beta-lactamase inhibitors and their preparation
CN111943950B (zh) * 2020-09-10 2022-03-29 山东安信制药有限公司 一种瑞来巴坦的制备方法
CN115448920B (zh) * 2022-10-14 2025-01-03 广州楷石医药有限公司 一种β-内酰胺酶抑制剂及其应用
CN116854623B (zh) * 2023-07-11 2025-08-05 齐鲁安替制药有限公司 一种阿维巴坦中间体的制备方法
CN117700415B (zh) * 2024-02-06 2024-04-30 成都四面体药物研究有限公司 含脲双环化合物、其用途、其制备的药物、其联合用药物及其复方制剂
CN119431373B (zh) * 2024-07-24 2025-08-08 科睿迪(南京)医药科技有限公司 一种β-内酰胺酶抑制剂及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2835186B1 (fr) * 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
US7632918B2 (en) * 2005-02-28 2009-12-15 Novartis Vaccines And Diagnostics, Inc. Semi-synthetic glycopeptides with antibiotic activity
CN101367804B (zh) * 2007-06-26 2010-12-15 山东轩竹医药科技有限公司 含有金刚烷的培南衍生物
PL2231667T3 (pl) 2008-01-18 2014-01-31 Merck Sharp & Dohme Inhibitory beta-laktamazy
EP2748165B1 (en) 2011-08-27 2016-11-02 Wockhardt Limited 1,6-diazabicyclo[3,2,1]octan-7-one derivatives and their use in the treatment of bacterial infections.
US9006230B2 (en) * 2011-08-30 2015-04-14 Wockhardt Ltd. 1,6-diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections
US8796257B2 (en) * 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
CN104334559B (zh) 2012-05-30 2017-03-22 明治制果药业株式会社 β‑内酰胺酶抑制剂及其制备方法
UA111925C2 (uk) 2012-12-11 2016-06-24 Федора Фармасьютікалз Інк. БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ
CA2897446A1 (en) 2013-02-06 2014-08-14 Astrazeneca Ab Combination therapy for the treatment of nosocomial pneumonia
WO2014141132A1 (en) * 2013-03-14 2014-09-18 Naeja Pharmaceutical Inc. NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS

Also Published As

Publication number Publication date
CN107531709B (zh) 2020-10-23
AU2016322283A1 (en) 2017-11-09
US10167283B2 (en) 2019-01-01
KR20170131661A (ko) 2017-11-29
TWI610930B (zh) 2018-01-11
CN107531709A (zh) 2018-01-02
WO2017045510A1 (zh) 2017-03-23
EP3281942A1 (en) 2018-02-14
JP2018515481A (ja) 2018-06-14
EP3281942A4 (en) 2018-08-15
CA2984024A1 (en) 2017-03-23
US20180148448A1 (en) 2018-05-31
TW201718584A (zh) 2017-06-01

Similar Documents

Publication Publication Date Title
MX2017013792A (es) INHIBIDORES DE íŸ-LACTAMASA Y USOS DE LOS MISMOS.
PH12016501379A1 (en) Azepane derivatives and methods of treating hepatitis b infections
WO2016109663A3 (en) Derivatives and methods of treating hepatitis b infections
WO2016011390A8 (en) Irak4 inhibiting agents
WO2016044556A3 (en) Arginine methyltransferase inhibitors and uses thereof
NZ730809A (en) Methods for treating filoviridae virus infections
NZ723107A (en) Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof
EP4193993A3 (en) Combinations of cannabinoids and n-acylethanolamines
NZ762034A (en) Human plasma kallikrein inhibitors
AU2015336400A8 (en) Novel Aminoalkyl benzothiazepine Derivatives And Uses Thereof
EA201790108A1 (ru) Гетероарильные соединения, пригодные в качестве ингибиторов sumo-активирующего фермента
GEP20186892B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
MX338610B (es) Composiciones farmaceuticas que comprenden sulbactam e inhibidor de beta-lactamasa.
CA2983481A1 (en) Janus kinase inhibitor
MX2016011556A (es) Composiciones que comprenden un agente amargante.
EA201691421A1 (ru) Гетероарилы и их применение
MX2016011558A (es) Composiciones que comprenden un agente amargante.
PH12015501588A1 (en) Compounds and methods for treating bacterial infections
MX2020007131A (es) Inhibidores de histona acetiltransferasa de la familia myst.
EP4268897A3 (en) Minocycline compounds for biodefense
MX2018014813A (es) Composiciones antibacterianas.
ZA202200511B (en) Ring-fused thiazolino 2-pyridones, methods for preparation thereof and their use in the treatment and/or prevention of tuberculosis
CA3035115C (en) Nitrogenous heterocyclic aromatic compound, preparation method therefor, pharmaceutical composition thereof, and application thereof
NZ730816A (en) Quinoline carboxamides for use in the treatment of multiple myeloma
WO2018125880A8 (en) Nrf2 activator